wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q52595142-01A83711-E5BF-4771-9A73-84D123B2CB85
Q52595142-01A83711-E5BF-4771-9A73-84D123B2CB85
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52595142-01A83711-E5BF-4771-9A73-84D123B2CB85
Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
P2860
Q52595142-01A83711-E5BF-4771-9A73-84D123B2CB85
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52595142-01A83711-E5BF-4771-9A73-84D123B2CB85
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4c022792113728876217762827f35aba22fb8d4d
P2860
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.